Table 1.
Baseline and clinical characteristics of treated patients (n=37)
| Characteristic | Total N = 37 |
MCL N = 18 |
FL N = 5 |
DLBCL N = 14 |
|---|---|---|---|---|
| Age, years, median (range) | 70 (48–84) | 71 (50–84) | 65 (56–84) | 72 (48–78) |
| Sex, n (%) | ||||
| F | 10 (27) | 2 (11) | 1 (20) | 7 (50) |
| M | 27 (73) | 16 (89) | 4 (80) | 7 (50) |
| Stage, n (%) | ||||
| II | 2 (5.4) | 1 (5.6) | 0 (0) | 1 (7.1) |
| III | 8 (22) | 0 (0) | 4 (80) | 4 (29) |
| IV | 27 (73) | 17 (94) | 1 (20) | 9 (64) |
| Prior lines of therapy, n (%) | ||||
| 1 | 14 (38) | 12 (67) | 0 (0) | 2 (14) |
| 2 | 15 (41) | 5 (28) | 5 (100) | 5 (36) |
| ≥ 3 | 8 (22) | 1 (5.6) | 0 (0) | 7 (50) |
| Prior stem cell transplant, n (%) | ||||
| Allogeneic | 4 (11) | 1 (5.6) | 2 (40) | 1 (7.1) |
| Autologous | 10 (27) | 6 (33) | 0 (0) | 4 (29) |
| None | 23 (62) | 11 (61) ` | 3 (60) | 9 (64) |
| Ki-67, n (%) | ||||
| < 30% | 10 (29) | 5 (31) | 4 (80) | 1 (7.1) |
| ≥ 30% | 25 (71) | 11 (69) | 1 (20) | 13 (93) |
| Unknown | 2 | 2 | 0 | 0 |
| Abnormal LDH (above ULN), n (%) | 15 (41) | 4 (22) | 1 (20) | 10 (71) |
| Lesion ≥ 5 cm, n (%) | 14 (38) | 8 (44) | 3 (60) | 3 (21) |
| Number extranodal sites, n (%) | ||||
| < 2 | 22 (59) | 10 (56) | 4 (80) | 8 (57) |
| ≥ 2 | 15 (41) | 8 (44) | 1 (20) | 6 (43) |
| Baseline SUVmax, median (range) | 13 (4–46) | 9 (4–16) | 16 (8–29) | 18 (8–46) |
| Total lesion glycolysis, median (range) | 804 (78–20,806) | 895 (78–20,806) | 928 (555–3,187) | 540 (88–7,146) |
| Tumor metabolic volume, cm3, median (range) | 148 (12–5,854) | 195 (12–5,854) | 152 (72–458) | 50 (12–762) |
Abbreviations: LDH, lactate dehydrogenase; SUVmax, maximum standardized uptake value; ULN, upper limit of normal.